Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
Date:6/3/2008

XI'AN, China, June 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, released an update on its business following their quarterly report released on May 20.

"In the first quarter, sales of our products increased substantially," stated company CEO Jing'An Wang. "Our revenue in the first quarter increased 85% versus 2007 and gross profit increased 140% to $977,000." Both of these figures represented record levels for HFGB. Mr. Wang further stated that net income was strong at 2 cents per share despite being negatively impacted by one-time expenses related to the company's recent financing activity. "Our company continues to execute to plan and there is no change to our earnings guidance of $4 million in net income for 2008."

In addition to the strength in the current business, Huifeng is gearing up for expected sales of Diosmin to Safic-Alcan under its agreement first announced last fall. As of the end of May 2008, in order to ensure smooth management operation during production of Diosmin and the integrity and reliability of COS certification materials, the company made a lot of improvements to its production technology and equipment, trained production workers and amended application documents; at the same time, plenty of testing research data, analytic testing and quality evaluation results in accordance with EP made by the company will be accomplished before June 20.

The company anticipates filing for COS Certification on August 5. As per the COS certification application process, it is estimated that the company will obtain a registration No. for Diosmin raw materials from the COS Certification Secretariat on September 15, at which time Huifeng will be able to implement its Diosmin sales contract with Safic.

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. http://www.hfgb.cn/

For more information, please contact:

Dan Carlson

Primary Capital LLC

Tel: +1-415-460-1165

Email: DCarlson@PrimaryLLC.com


'/>"/>
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
2. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
3. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
6. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
9. NxStage Medical Provides Update on Medisystems Acquisition
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. Signalife Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Patient Monitoring and Diagnostic ... connectivity to reduce the amount of wiring in a healthcare facility and allow ... devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, and other wearable ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... cells for research and the development of cardiac regeneration therapies. The development ... numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of ...
(Date:5/23/2017)... ... May 23, 2017 , ... Vortex Biosciences , provider of circulating ... prostate circulating tumor cells using Vortex microfluidic technology ” in Nature Precision Oncology on ... Dr. Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los ...
(Date:5/23/2017)... ... 2017 , ... Cambridge Semantics , the leading provider of Big Data ... Conference and Expo in Boston May 23-25 with a featured speaker and solution ... Data Lake is also a finalist for the Best of Show award. , James ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):